Concentration of ABNCoV2-specific Antibodies 14 Days Following First Vaccination;Number of at Least Possibly Related Grade 3 Adverse Events (AE) and Serious Adverse Events (SAE)

Concentration of ABNCoV2-specific Antibodies 14 Days Following First Vaccination;Number of at Least Possibly Related Grade 3 Adverse Events (AE) and Serious Adverse Events (SAE)

Primary immunogenicity endpoint: Concentration of ABNCoV2-specific antibodies;Primary safety endpoint: Number of at least possibly related Grade 3 adverse events (AE) and serious adverse events (SAE)

Primary immunogenicity endpoint: Concentration of ABNCoV2-specific antibodies;Primary safety endpoint: Number of at least possibly related Grade 3 adverse events (AE) and serious adverse events (SAE)